Christine B. Jensen
Novo Nordisk (Denmark)(DK)
Publications by Year
Research Areas
Metabolism, Diabetes, and Cancer, Diabetes Treatment and Management, Adipose Tissue and Metabolism, Birth, Development, and Health, Diet and metabolism studies
Most-Cited Works
- → A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management(2015)2,489 cited
- → Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes(2015)1,110 cited
- → TXNIP Regulates Peripheral Glucose Metabolism in Humans(2007)496 cited
- → Impact of short‐term high‐fat feeding on glucose and insulin metabolism in young healthy men(2009)266 cited
- → A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes(2015)220 cited
- → Deoxyribonucleic Acid Methylation and Gene Expression of PPARGC1A in Human Muscle Is Influenced by High-Fat Overfeeding in a Birth-Weight-Dependent Manner(2010)189 cited
- → Early Differential Defects of Insulin Secretion and Action in 19-Year-Old Caucasian Men Who Had Low Birth Weight(2002)182 cited
- → Semaglutide, a once‐weekly human GLP‐1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel(2014)160 cited
- → Targeted pharmacological therapy restores β-cell function for diabetes remission(2020)144 cited
- → Altered Skeletal Muscle Fiber Composition and Size Precede Whole-Body Insulin Resistance in Young Men with Low Birth Weight(2007)139 cited